Blood and Marrow Transplant Program, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio.
Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Cancer. 2021 Feb 15;127(4):609-618. doi: 10.1002/cncr.33232. Epub 2020 Oct 21.
The association of community factors and outcomes after hematopoietic cell transplantation (HCT) has not been comprehensively described. Using the County Health Rankings and Roadmaps (CHRR) and the Center for International Blood and Marrow Transplant Research (CIBMTR), this study evaluated the impact of community health status on allogeneic HCT outcomes.
This study included 18,544 adult allogeneic HCT recipients reported to the CIBMTR by 170 US centers in 2014-2016. Sociodemographic, environmental, and community indicators were derived from the CHRR, an aggregate community risk score was created, and scores were assigned to each patient (patient community risk score [PCS]) and transplant center (center community risk score [CCS]). Higher scores indicated less healthy communities. The impact of PCS and CCS on patient outcomes after allogeneic HCT was studied.
The median age was 55 years (range, 18-83 years). The median PCS was -0.21 (range, -1.37 to 2.10; standard deviation [SD], 0.42), and the median CCS was -0.13 (range, -1.04 to 0.96; SD, 0.40). In multivariable analyses, a higher PCS was associated with inferior survival (hazard ratio [HR] per 1 SD increase, 1.04; 99% CI, 1.00-1.08; P = .0089). Among hematologic malignancies, a tendency toward inferior survival was observed with a higher PCS (HR, 1.04; 99% CI, 1.00-1.08; P = .0102); a higher PCS was associated with higher nonrelapse mortality (NRM; HR, 1.08; 99% CI, 1.02-1.15; P = .0004). CCS was not significantly associated with survival, relapse, or NRM.
Patients residing in counties with a worse community health status have inferior survival as a result of an increased risk of NRM after allogeneic HCT. There was no association between the community health status of the transplant center location and allogeneic HCT outcomes.
社区因素与造血细胞移植(HCT)后的结果之间的关联尚未得到全面描述。本研究使用县健康排名和路线图(CHRR)和国际血液和骨髓移植研究中心(CIBMTR),评估了社区健康状况对异基因 HCT 结果的影响。
本研究纳入了 2014 年至 2016 年期间,170 个美国中心向 CIBMTR 报告的 18544 例成人异基因 HCT 受者。社会人口统计学、环境和社区指标源自 CHRR,创建了一个综合社区风险评分,并为每位患者(患者社区风险评分 [PCS])和移植中心(中心社区风险评分 [CCS])分配评分。较高的分数表示社区健康状况较差。研究了 PCS 和 CCS 对异基因 HCT 后患者结局的影响。
中位年龄为 55 岁(范围,18-83 岁)。中位 PCS 为-0.21(范围,-1.37 至 2.10;标准差 [SD],0.42),中位 CCS 为-0.13(范围,-1.04 至 0.96;SD,0.40)。在多变量分析中,PCS 较高与生存不良相关(每增加 1 SD 的风险比 [HR],1.04;99%CI,1.00-1.08;P=.0089)。在血液系统恶性肿瘤中,较高的 PCS 与生存不良的趋势相关(HR,1.04;99%CI,1.00-1.08;P=.0102);较高的 PCS 与较高的非复发死亡率(NRM;HR,1.08;99%CI,1.02-1.15;P=.0004)相关。CCS 与生存、复发或 NRM 无显著相关性。
居住在社区健康状况较差的县的患者,由于异基因 HCT 后 NRM 风险增加,生存状况较差。移植中心所在社区的健康状况与异基因 HCT 结果之间没有关联。